Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
all-trans-4-hydroxy Retinoic acid is a metabolite of all-trans retinoic acid (Item No. 11017) formed by the cytochrome P450 (CYP) isoforms CYP26A1, B1, and C1.1,2 It binds to retinoic acid receptors (RARs) with a lower affinity than other all-trans retinoic acid metabolites (IC50s = 606, 298, and 892 nM for RARα, RARβ, and RARγ, respectively, in a radioligand binding assay). It also transactivates RARs with a lower efficacy than other metabolites (EC50s = 791, 64, and 94 nM for RARα, RARβ, and RARγ, respectively) but induces transcription of a reporter plasmid equipotently. all-trans-4-hydroxy Retinoic acid inhibits cell growth, halts the cell cycle in the G1 phase, and induces differentiation of NB4 acute promyelocytic leukemia cells (EC50 = 79.8 nM).3
WARNING This product is not for human or veterinary use.
1. Activation of retinoic acid receptor-
2. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-
3. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-